

# Clinical Outcomes of Utilization of Stress Ulcer Prophylaxis in Hospitalized, Non-ICU Patients

Paige Robinson, DO, PGY-2 and Kate Radvansky, DO

# BACKGROUND

## Goal

This study is a retrospective chart review that aims to measure the effect of stress ulcer prophylaxis in hospitalized non-ICU level patients to determine the clinical effect of the presence or absence of stress ulcer prophylaxis.

# Definition, Pathogenesis, Incidence of Stress Ulcers

### **Definition**

Superficial ulceration, erosion of gastric mucosa

Most commonly in stomach, but can occur in duodenum or esophagus

## Pathogenesis<sup>1-3</sup>

Acid hyper secretion (especially neurologic and thermal injuries) due to excess gastric stimulation of parietal cells

Also stimulated by stress-triggered vagal stimulation

Pro-inflammatory state causes release of mediators: arachidonic acid metabolites, cytokines, oxygen free radicals

Impaired mucosal protection

Decreased perfusion

Increased concentration of refluxed bills salts and uremic toxins

Synthesis decreased due to poor gut perfusion from shock, sepsis, trauma

Start proximally in the acid-secreting portion of stomach, then progresses: over time, become deeper and move distally

Wedge-shaped mucosal hemorrhages with necrosis of superficial mucosal cells; if progresses to submucosa, can cause significant and life-threatening bleeding

## Incidence<sup>4-7</sup>

Range: 0.005% to 7.85%

\*Depending on study, definition of clinically important bleeding, or risk factors present

## Independent Risk Factors for Stress Ulcer Formation<sup>1,8</sup>


•Age >60

- Anticoagulation +/- antiplatelet agent
- Male NSAID and corticosteroid
- Liver disease Dual Antiplatelet Therapy (DAPT)
- Acute renal failure (AKI)Sepsis

## Definition of Clinically Important Bleeding

- Transfusion
- Endoscopic Evaluation or Intervention
- Perforation or Surgical Intervention
- ICU Upgrade
- Overt GI Bleeding


# **PROTOCOL**



therapeutic purpose

(GI Bleed, GERD, etc.)

Included: all remaining patients



Analysis: Rates of clinically important bleeding per group?

# RESULTS: RATES OF BLEEDING




Figure 1. Percent of patients with clinically important bleeding (CIB) based on the use of stress ulcer prophylaxis. Three of 190 patients in the underuse category had clinically important bleeding events. Three of 46 patients with correct use of prophylaxis had events. The result of an ANOVA was p = 0.156, conferring no statistical significance.

# DISCUSSION

## Patients with Clinically Important Bleeding Events

#### Patient #1

- Underuse of Prophylaxis
- Risk factors: male, NSAID and steroid, AKI, sepsis
- Event: Transfusion, Scope

#### Patient #2

- Underuse of Prophylaxis
- Risk factors: age, male, anticoagulation
- Event: Overt GI bleeding

#### Patient #3

- Underuse of Prophylaxis
- Risk factors: age, male, DAPT,
  AKI
- Event: Transfusion

#### Patient #4

- Correct use of Prophylaxis
- Risk factors: age, male, AKI, liver disease
- Event: Transfusion, ICU
  Upgrade, Death

#### Patient #5

- Correct use of Prophylaxis
- Risk factors: age, male, anticoagulation
- Event: scope

#### Patient #6

- Correct use of Prophylaxis
- Risk factors: AKI
- Event: Transfusion

# CONCLUSION

There is no statistically significant difference in clinically important bleeding based on correct or incorrect use of stress ulcer prophylaxis in hospitalized, non-ICU patients. This is consistent with previous literature. Use of stress ulcer prophylaxis on floor patients remains individualized by the clinician, who must give consideration to the specific patient and risk factors present. Further studies are needed to determine if a certain number or combination of risk factors is significant rather than individual risk factors.

# REFERENCES

- 1. Cook, D., Guyatt, G. 2018. "Review Article: prophylaxis against upper gastrointestinal bleeding in hospitalized patients." *NEJM* 378 (26): 2506-2516.
- 2. American Society of Health-System Pharmacists. "ASHP therapeutic guidelines on stress ulcer prophylaxis." *Am J Health-Syst Pharm*. 1999; 56:347-79.
- 3. Weinhouse, G., Manaker, S., Finlay, G. 2019. "Stress ulcer prophylaxis in the intensive care unit." *UpToDate*.
- 4. Qadeer, M, Richter, J., Brotman, D. 2006. "Hospital-acquired gastrointestinal bleeding outside the critical care unit." *Journal of Hospital Medicine* **1** (1): 14-20.
- 5. Terdiman, J., Ostroff, J. 1998. "Gastrointestinal bleeding in the hospitalized patient: a case-controlled study to assess risk factors, causes, and outcome." *Am J Med* **104**: 349-354.
- 6. Fiaccadori, E., et al. 2001. "Incidence, risk factors, and prognosis of gastrointestinal hemorrhage complicating acute renal failure." *Kidney Int* **59:** 1510-1519.
- 7. Herzig, S., Rotheberg, M., Feinbloom, D. 2013. "Risk factors for nosocomial gastrointestinal bleeding and use of acid-suppressive medication in non-critically ill patients." *J Gen Intern Med* **28**: 683-690.
- 8. Bui, T. 2019. "Adult Acid Suppression Guidelines." The Capsule 1: 1-2.